Details

Autor(en) / Beteiligte

• Lasolle, Hélène
• Cortet, Christine
• Castinetti, Fréderic
• Cloix, Lucie
• Caron, Philippe
• Delemer, Brigitte
• Desailloud, Rachel
• Jublanc, Christel
• Lebrun-Frenay, Christine
• Sadoul, Jean-Louis
• Taillandier, Luc
• Batisse-Lignier, Marie
• Bonnet, Fabrice
• Bourcigaux, Nathalie
• Bresson, Damien
• Chabre, Olivier
• Chanson, Philippe
• Garcia, Cyril
• Haissaguerre, Magalie
• Reznik, Yves
• Borot, Sophie
• Villa, Chiara
• Vasiljevic, Alexandre
• Gaillard, Stephan
• Jouanneau, Emmanuel
• Assié, Guillaume
• Raverot, Gérald

Titel

Temozolomide treatment can improve overall survival in aggressive pituitary tumors and pituitary carcinomas

Ist Teil von

• European journal of endocrinology, 2017-06, Vol.176 (6), p.769

Ort / Verlag

England

Erscheinungsjahr

2017

Quelle

MEDLINE

Beschreibungen/Notizen

• Only few retrospective studies have reported an efficacy rate of temozolomide (TMZ) in pituitary tumors (PT), all around 50%. However, the long-term survival of treated patients is rarely evaluated. We therefore aimed to describe the use of TMZ on PT in clinical practice and evaluate the long-term survival. Multicenter retrospective study by members of the French Society of Endocrinology. Forty-three patients (14 women) treated with TMZ between 2006 and 2016 were included. Most tumors were corticotroph (  = 23) or lactotroph (  = 13), and 14 were carcinomas. Clinical/pathological characteristics of PT, as well as data from treatment evaluation and from the last follow-up were recorded. A partial response was considered as a decrease in the maximal tumor diameter by more than 30% and/or in the hormonal rate by more than 50% at the end of treatment. The median treatment duration was 6.5 cycles (range 2-24), using a standard regimen for most and combined radiotherapy for six. Twenty-two patients (51.2%) were considered as responders. Silent tumor at diagnosis was associated with a poor response. The median follow-up after the end of treatment was 16 months (0-72). Overall survival was significantly higher among responders (  = 0.002); however, ten patients relapsed 5 months (0-57) after the end of TMZ treatment, five in whom TMZ was reinitiated without success. Patients in our series showed a 51.2% response rate to TMZ, with an improved survival among responders despite frequent relapses. Our study highlights the high variability and lack of standardization of treatment protocols.